Lever
Lifestyle
- Regular cardiovascular exercise
- Weight management
- Smoking cessation
Blutwerte · Marker
NT-proBNP
N-terminal pro-BNP · NT-pro-B-type Natriuretic Peptide · BNP
Herzmarker
- Einheit:
- pg/mL
NT-proBNP quantifies the concentration of N-terminal prohormone of brain natriuretic peptide in the blood, reflecting cardiac wall stress.
Reference Ranges
Reference
0–125pg/mL
0
125
LowNormalHigh
Reference
Unit · pg/mLReference ranges may vary with age and renal function; higher levels are common in older adults.
Overview
Übersicht
NT-proBNP, or N-terminal pro-B-type Natriuretic Peptide, is a peptide biomarker that is cleaved from the prohormone of brain natriuretic peptide (BNP) and released into the bloodstream. It is primarily secreted by cardiac myocytes in response to increased cardiac wall stress, often due to heart failure or other cardiac conditions. Researchers have found that NT-proBNP levels are indicative of cardiac function and can be used to assess heart failure severity and prognosis. Clinically, NT-proBNP is a critical marker for diagnosing and managing heart failure, as well as evaluating the risk in pulmonary arterial hypertension (PAH). Elevated levels are associated with increased cardiac stress, while lower levels may indicate improved cardiac function or effective treatment. In the context of athletic performance and biohacking, NT-proBNP can be used to monitor cardiac health, especially in endurance athletes who may experience cardiac remodeling. However, its role in longevity is less clear, as elevated levels are typically associated with pathological conditions. Caveats include potential confounders such as renal function, age, and obesity, which can affect NT-proBNP levels. Time of day and fasting status do not significantly impact NT-proBNP measurements, but it is important to consider these factors when interpreting results.
Klinische Bedeutung
Elevated NT-proBNP levels indicate cardiac stress and are used to diagnose and manage heart failure and pulmonary arterial hypertension. Reduced levels suggest improved cardiac function or effective treatment.
Dynamics
Trend Interpretation
Rising Values
Progressively rising NT-proBNP values suggest worsening cardiac function. Re-test in 4 weeks if outside optimal range.
Falling Values
Progressively falling values indicate improving cardiac function or effective treatment.
Re-test Interval
4 weeks if outside optimal range
Etiology
Causes — High & Low
Cause
Elevated Levels
- Heart failure
- Pulmonary arterial hypertension
- Renal dysfunction
- Acute coronary syndrome
- Atrial fibrillation
Cause
Low Levels
- Effective heart failure treatment
- Improved cardiac function
- Low cardiac stress
- Young age
Protocol
How to Optimize
Lever
Nutrition
- Low-sodium diet
- Increased fruit and vegetable intake
Note:
Consult healthcare provider for personalized interventions, especially in the presence of heart disease.
Testing Guidelines
✓Fasting Not Required
✓Not Time-Sensitive
Testing Frequency
Every 6 months for heart failure patients, annually for high-risk individuals
Interfering Factors
- Renal impairment
- Obesity
- Age-related changes
Related Peptides & Hormones
Bnp
hormone or peptideCorrelated with
Open Research Questions
Current research suggests that reference ranges and optimal targets for NT-proBNP in specific populations, such as those with Takayasu arteritis, remain debated. Researchers have not yet established the impact of confounding factors like exercise on NT-proBNP levels in diverse clinical settings. Additionally, unanswered clinical questions include the biomarker's role in predicting long-term outcomes in pulmonary arterial hypertension and its comparative effectiveness against other biomarkers in various disease states.
31 Research Publications
271
Total Citations
12
Human/RCT
2.0
Avg. Influence
2024
Latest
Sort
Filter
01Top
#01
N-Terminal B-type Natriuretic Peptide in Heart Failure.
ReviewInfluence1.0
59
This study focused on the use of NT-proBNP as a biomarker in heart failure (HF). Researchers found that NT-proBNP is effective in diagnosing acute decompensated HF and provides prognostic information independent of standard clinical predictors. It remains the preferred marker for assessing cardiac status in patients receiving ARNI treatment.
02Top
#02
Evidence based application of BNP/NT-proBNP testing in heart failure.
ReviewInfluence2.0
50
This review summarized evidence on the application of BNP and NT-proBNP testing in heart failure. Researchers highlighted the importance of these biomarkers in diagnosing heart failure and discussed their potential roles in prognosis and therapy guidance.
03Top
#03
NT-proBNP in Different Patient Groups of COPD: A Systematic Review and Meta-Analysis.
Meta-AnalysisInfluence6.0
34
Researchers conducted a systematic review to evaluate NT-proBNP levels in COPD patients. They found that NT-proBNP levels were significantly higher in patients with acute exacerbations and those with severe COPD, indicating its potential role in assessing cardiovascular stress.
04
#04
Detection of cardioembolic stroke with B-type natriuretic peptide or N-terminal pro-BNP: a comparative diagnostic meta-analysis.
Meta-AnalysisInfluence2.0
32
This meta-analysis compared the diagnostic efficacy of BNP and NT-proBNP in detecting cardioembolic stroke. Researchers found that while BNP showed higher sensitivity, NT-proBNP demonstrated superior specificity in distinguishing cardioembolic from non-cardioembolic strokes in adult ischemic stroke patients.
05
#05
Angiotensin Receptor-Neprilysin Inhibitors and the Natriuretic Peptide Axis.
ReviewInfluence1.0
20
This review discussed the effects of angiotensin receptor-neprilysin inhibitor (ARNI) therapy on the natriuretic peptide axis, including NT-proBNP. Researchers found that ARNI therapy decreases NT-proBNP levels while improving echocardiographic parameters, suggesting a link between NT-proBNP changes and cardiac function.
06
#06
Biomarkers in Takayasu arteritis.
Wen Dan, et al. · International journal of cardiology · 2023
Review
17
This review explored the role of various biomarkers, including NT-proBNP, in Takayasu arteritis, a rare vasculitis. Researchers observed that these biomarkers are valuable for early diagnosis, evaluating disease activity, and guiding treatment options, highlighting their clinical significance.
Key findings
- 01Researchers observed that Takayasu arteritis involves complex interactions between immune system components and inflammation.
- 02They identified several biomarkers, including cytokines and autoantibodies, that may help in understanding the disease.
- 03The study highlights the need for further research to clarify the role of these biomarkers in Takayasu arteritis.
07
#07
Standardization of cardiac markers.
Review
16
This review focused on the standardization of cardiac biomarkers, including NT-proBNP. Researchers found that developing primary reference materials and quality specifications for assays is essential for optimizing the clinical use of cardiac biomarkers worldwide.
08
#08
Cardiac Biomarkers in Patients With Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial.
Human
11
Researchers found that higher levels of NT-proBNP in patients with asymptomatic severe aortic stenosis were associated with higher event rates for adverse outcomes. However, the study suggested limited value for single measurements of NT-proBNP to guide the timing of transcatheter aortic valve replacement.
09
#09
High-Sensitivity Troponin T, NT-proBNP, and Cognitive Outcomes in SPRINT.
HumanInfluence1.0
5
In the SPRINT study, researchers found that lower levels of NT-proBNP were associated with greater cognitive benefits from intensive blood pressure treatment. Higher NT-proBNP levels indicated a higher risk of mild cognitive impairment or probable dementia.
10
#10
The Indian Consensus Document on cardiac biomarker.
Review
5
This study examined the role of cardiac biomarkers in diagnosing and managing heart failure in India. Researchers found that biomarkers can indicate the presence and severity of congestive heart failure (CHF) and may provide clinical benefits compared to conventional assessments.
Clinical Trials (11)
11
Total Trials
2,957
Total Enrolled
Mandibular Advancement to Reduce Ventricular Load and Improve Quality-of-life in Heart Failure
NCT07460505NOT_YET_RECRUITING
Sponsor
National University Hospital, Singapore
Enrollment
328
Started
2026
Primary outcome
N-terminal pro-B-type natriuretic peptide (NT-pro BNP)
Heart FailureOSA - Obstructive Sleep Apnea
The Assessment of Partial Guideline-Directed Medical Therapy Down Titration in Heart Failure in Remission.
Sponsor
Ziekenhuis Oost-Limburg
Enrollment
100
Started
2026
Primary outcome
Time to first occurrence of recurrent adverse remodeling, significant NT-proBNP increase or all-cause mortality.
Heart Failure
Early Diagnosis of Heart Failure Using NT-proBNP Levels in Primary Care
NCT07059260NOT_YET_RECRUITING
Sponsor
Maimónides Biomedical Research Institute of Córdoba
Enrollment
304
Started
2025
Primary outcome
Clinical benefit based on a hierarchical composite outcome (win ratio approach)
Heart Failure
NT-ProBNP-based Heart Failure Screening and Prevention Trial in Patients With Type 2 Diabetes: STRONG-DM Study
NCT06593327RECRUITING
Sponsor
University of Texas Southwestern Medical Center
Enrollment
300
Started
2025
Primary outcome
Incident Heart Failure or All-cause death
Type 2 DiabetesDiabetic CardiomyopathyHeart FailureCardiometabolic Diseases
SGLT2 for Heart Failure in CHD Patients
NCT05897489UNKNOWN
Sponsor
Centre Hospitalier Universitaire de Nice
Enrollment
100
Started
2023
Primary outcome
To evaluate, on real-life data, the efficacy of iSGLT2 in patients with heart failure related to congenital heart disease as defined by improvement in NYHA class and/or change in NT-proBNP.
Heart Failure
NT-proBNP Measurements to Rule-out Heart Failure Among Patients With Atrial Fibrillation: A Prospective Clinical Study
NCT04125966UNKNOWN
Sponsor
University of Aarhus
Enrollment
403
Started
2019
Primary outcome
Diagnostic performance of NT-proBNP for ruling out heart failure in atrial fibrillation patients
Atrial FibrillationHeart Failure
Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
Sponsor
Eidos Therapeutics, a BridgeBio company
Enrollment
632
Started
2019
Primary outcome
A Hierarchical Combination of All-Cause Mortality, Cumulative Frequency of CV-related Hospitalization, Change From Baseline in NT-proBNP and Change From Baseline in 6MWT at the Last Available Visit Where Both Subjects Had Non-missing Assessments.
AmyloidosisAmyloid CardiomyopathyTransthyretin AmyloidosisCardiomyopathiesHeart Diseases
Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction
Sponsor
Morten Schou
Enrollment
190
Started
2017
Primary outcome
Between-group difference in the change of plasma concentrations of NT-proBNP
Heart Failure With Reduced Ejection Fraction
Urine NT-ProBNP in Neonatal Respiratory Distress
NCT02020993UNKNOWN
Sponsor
Ankara University
Enrollment
150
Started
2013
Primary outcome
severity of respiratory distress
Neonatal Respiratory Distress
Is There a Correlation of Natriuretic Propeptide Type B With an Intraoperative Low Cardiac Output?
NCT00586027COMPLETED
Sponsor
Klinikum Ludwigshafen
Enrollment
150
Started
2008
Primary outcome
The primary objective is to monitor NT-proBNP for 7 days in patients with an intraoperative low cardiac output. Cardiac index and NT-proBNP will be correlated with morbidity and mortality.
Cardiac SurgeryLow Cardiac OutputNatriuretic Peptide B
Nt-proBNP Guided Primary Prevention of CV Events in Diabetic Patients
Sponsor
Medical University of Vienna
Enrollment
300
Started
2007
Primary outcome
Reduction in cardiac events
Diabetes MellitusHeart FailureCoronary Artery Disease
Publication Trend
Research publications about NT-proBNP over time
3totalTrack your bloodwork in PepStack
Log lab results, track trends and optimize your biomarkers over time.
Legal Disclaimer
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer